獣医自己免疫疾患治療薬の世界市場レポート 2025年

獣医自己免疫疾患治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で44億8,000万米ドルに成長します。予測期間の成長は、バイオテクノロジーの進歩、動物ヘルスケアへの投資の増加、ペットの自己免疫疾患の有病率の増加、新規治療薬の開発、ペット保険導入の増加に起因します。予測期間の主な動向には、個別化医療、生物製剤の使用、遠隔医療の統合、再生療法の採用、ホリスティック・統合治療の重視などがあります。個別化医療、生物製剤の使用、遠隔医療の統合、再生療法の採用、ホリスティック・統合治療の重視などです。

獣医療における研究資金の増加は、今後数年間の同市場の成長を促進すると予想されます。動物の疾病、障害、傷害の予防、診断、治療に重点を置く獣医学は、人獣共通感染症の増加、ペット産業の拡大、動物の健康における技術の進歩、農業のニーズ、野生動物の保護活動などのさまざまな要因により、より多くの資金を受けています。このような資金提供の増加は、病気のメカニズム、診断ツール、治療法に関する研究を含む、獣医自己免疫疾患に関する研究を支援するものであり、これにより、これらの疾患を効果的に診断し、管理する能力を向上させるものです。例えば、米国立食農研究所は2024年8月、米国全土の2022会計年度に320万米ドルを農村部の食用動物獣医学に投資する「獣医サービス補助金プログラム」を発表しました。従って、獣医学における研究資金の増加が獣医自己免疫疾患治療薬市場の成長を促進しています。

獣医自己免疫疾患治療薬市場の主な企業は、RenBiologicsのような先進技術ソリューションの開発に注力し、業界の主要なニーズに応えています。RenBiologics社は、腎臓関連の疾患や慢性疾患に対する革新的な治療法の創出を専門としており、腎機能や移植成功などの転帰を改善するための生物製剤や再生医療に焦点を当てています。例えば、2024年1月、中国のバイオテクノロジー企業であるBiocytogenは、治療開発のための完全ヒト抗体のライセンシングに特化した新しいサブブランド、RenBiologicsを立ち上げました。このイニシアチブは、独自のRenMiceプラットフォームを使用して作成された、バイオサイトーゲンの40万を超える完全ヒト抗体配列の広範なライブラリーを活用することを目的としています。RenBiologicsは、これらの抗体の共同開発やライセンシングを行う製薬企業やバイオテクノロジー企業との提携を支援し、抗体を用いた新規治療薬の可能性を高めます。今回の発売は、抗体創製の世界リーダーとなり、複数の治療領域における革新的な治療法の開発を加速させるというバイオサイトーゲンのコミットメントを強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界獣医自己免疫疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の獣医自己免疫疾患治療薬市場：成長率分析
• 世界の獣医自己免疫疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界の獣医自己免疫疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界獣医自己免疫疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の獣医自己免疫疾患治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• アザチオプリン
• シクロスポリン
• ミコフェノール酸
• レフルノミド
• シクロホスファミド
• レボチロキシン
• 葉酸
• ヒドロキシクロロキン
• クロロキン
• 世界の獣医自己免疫疾患治療薬市場動物の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コンパニオンアニマル
• 家畜
• その他の動物
• 世界の獣医自己免疫疾患治療薬市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 甲状腺機能低下症
• 天疱瘡
• 犬のループス
• 自己免疫性溶血性貧血
• 水疱性類天疱瘡
• 円板状エリテマトーデス（DLE）
• 免疫関連関節炎
• その他の病気
• 世界の獣医自己免疫疾患治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動物病院
• 獣医クリニック
• 世界の獣医自己免疫疾患治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• プレドニゾロン
• デキサメタゾン
• メチルプレドニゾロン
• トリアムシノロン
• 世界の獣医自己免疫疾患治療薬市場アザチオプリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アザチオプリン経口錠
• アザチオプリン注射剤
• 世界の獣医自己免疫疾患治療薬市場シクロスポリンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口シクロスポリン（アトピカ）
• 注射用シクロスポリン
• 世界の獣医自己免疫疾患治療薬市場ミコフェノール酸のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ミコフェノール酸モフェチル（経口剤）
• ミコフェノール酸ナトリウム（注射剤）
• 世界の獣医自己免疫疾患治療薬市場レフルノミドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レフルノミド錠（経口）
• レフルノミド注射剤
• 世界の獣医自己免疫疾患治療薬市場シクロホスファミドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口シクロホスファミド
• 注射用シクロホスファミド
• 世界の獣医自己免疫疾患治療薬市場レボチロキシンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• レボチロキシンナトリウム錠（経口）
• レボチロキシンナトリウム注射液
• 世界の獣医自己免疫疾患治療薬市場葉酸の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 葉酸サプリメント（経口）
• 注射用葉酸
• 世界の獣医自己免疫疾患治療薬市場ヒドロキシクロロキンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒドロキシクロロキン錠（経口）
• ヒドロキシクロロキン注射剤
• 世界の獣医自己免疫疾患治療薬市場クロロキンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロロキン錠（経口）
• クロロキン注射剤

第7章 地域別・国別分析

• 世界の獣医自己免疫疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の獣医自己免疫疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 獣医自己免疫疾患治療薬市場：競合情勢
• 獣医自己免疫疾患治療薬市場：企業プロファイル
  • Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline
• Takeda Pharmaceutical Company
• Amgen Inc.
• Teva Pharmaceuticals Industries Ltd.
• Zoetis Inc
• Boehringer Ingelheim International GmbH
• Sumitomo Pharma Co. Ltd.
• IDEXX Laboratories Inc.
• Cipla Inc.
• Mallinckrodt Pharmaceuticals
• Virbac S.A
• Dechra Pharmaceuticals plc
• Neogen Corporation
• Vetoquinol S.A.
• Norbrook Laboratories Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 獣医自己免疫疾患治療薬市場2029：新たな機会を提供する国
• 獣医自己免疫疾患治療薬市場2029：新たな機会を提供するセグメント
• 獣医自己免疫疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Veterinary autoimmune disease therapeutics encompass treatments tailored to manage and alleviate animal autoimmune conditions. These therapies are geared towards modulating or suppressing the immune response to mitigate inflammation, halt further tissue damage, and enhance the overall well-being and quality of life of affected animals. Given the complexity of these conditions, veterinary autoimmune disease therapeutics necessitate a customized approach, taking into account the specific disease, its severity, and the individual needs of the animal.

The primary types of therapy within veterinary autoimmune disease therapeutics include corticosteroids, azathioprine, cyclosporine, mycophenolate, leflunomide, cyclophosphamide, levothyroxine, folic acid, hydroxychloroquine, and chloroquine. Corticosteroids, derived from steroid hormones produced in the adrenal cortex, are commonly utilized in medicine to diminish inflammation and suppress immune activity. They are administered to various animals, including companion and livestock animals, to address conditions such as disease-type hypothyroidism, pemphigus disease, canine lupus, autoimmune hemolytic anemia, bullous pemphigoid, discoid lupus erythematosus (DLE), immune-related arthritis, among others. These therapeutic agents are typically dispensed through veterinary hospitals and clinics.

The veterinary autoimmune disease therapeutics research report is one of a series of new reports from The Business Research Company that provides veterinary autoimmune disease therapeutics market statistics, including the veterinary autoimmune disease therapeutics industry's global market size, regional shares, competitors with a veterinary autoimmune disease therapeutics market share, detailed veterinary autoimmune disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary autoimmune disease therapeutics industry. This veterinary autoimmune disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The veterinary autoimmune disease therapeutics market size has grown strongly in recent years. It will grow from $3.25 billion in 2024 to $3.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to advances in immunology, increased pet ownership, improved diagnostic methods, development of new drug classes, and rising awareness of pet health.

The veterinary autoimmune disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in biotechnology, growing investment in veterinary healthcare, increasing prevalence of autoimmune diseases in pets, development of novel therapeutics, and rising pet insurance adoption. Major trends in the forecast period include personalized medicine, the use of biologics, the integration of telemedicine, adoption of regenerative therapies, and focus on holistic and integrative treatments personalized medicine, use of biologics, integration of telemedicine, adoption of regenerative therapies, and focus on holistic and integrative treatments.

The increased funding for research in veterinary medicine is anticipated to drive the growth of the veterinary autoimmune disease therapeutics market in the coming years. Veterinary medicine, which focuses on preventing, diagnosing, and treating diseases, disorders, and injuries in animals, is receiving more funding due to various factors such as rising zoonotic diseases, the expanding pet industry, technological advancements in animal health, agricultural needs, and wildlife conservation efforts. This increased funding supports research on veterinary autoimmune diseases, including studies on disease mechanisms, diagnostic tools, and treatment options, thereby enhancing the ability to diagnose and manage these conditions effectively. For example, the National Institute of Food and Agriculture announced the Veterinary Service Grants Program in August 2024, investing $3.2 million in rural food animal veterinary medicine in the fiscal year 2022 across the United States. Hence, the heightened research funding in veterinary medicine is propelling the growth of the veterinary autoimmune disease therapeutics market.

Major companies in the veterinary autoimmune disease therapeutics market are focusing on developing advanced technological solutions, such as RenBiologics, to meet key industry needs. RenBiologics specializes in creating innovative therapies for kidney-related conditions and chronic diseases, with a focus on biologics and regenerative medicine to improve outcomes in areas like renal function and transplant success. For example, in January 2024, Biocytogen, a China-based biotechnology company, launched a new sub-brand, RenBiologics, to focus on the out-licensing of fully human antibodies for therapeutic development. This initiative aims to leverage Biocytogen's extensive library of over 400,000 fully human antibody sequences, created using its proprietary RenMice platform. RenBiologics will support collaborations with pharmaceutical and biotechnology companies for co-development and licensing of these antibodies, advancing the potential for novel antibody-based therapeutics. The launch underscores Biocytogen's commitment to becoming a global leader in antibody discovery and accelerating the development of innovative treatments across multiple therapeutic areas.

In March 2024, AbbVie Inc., a US-based biopharmaceutical company specializing in medicines and solutions for complex health issues, acquired Landos Biopharma for $137.5 million. This acquisition enables AbbVie to expand its portfolio in inflammatory bowel diseases by advancing innovative therapies such as NX-13, addressing significant unmet needs in patient care. Landos Biopharma, also based in the US, focuses on developing autoimmune therapies, with potential applications for treating similar conditions in animals.

Major companies operating in the veterinary autoimmune disease therapeutics market are Pfizer Inc, Merck & Co Inc, AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company, Amgen Inc., Teva Pharmaceuticals Industries Ltd., Zoetis Inc, Boehringer Ingelheim International GmbH, Sumitomo Pharma Co. Ltd., IDEXX Laboratories Inc., Cipla Inc., Mallinckrodt Pharmaceuticals, Virbac S.A, Dechra Pharmaceuticals plc, Neogen Corporation, Vetoquinol S.A., Norbrook Laboratories Limited, Heska Corporation, Bimeda Holdings PLC, Bayer Animal Health Inc, Aratana Therapeutics Inc, Hester Biosciences Limited

North America was the largest region in the veterinary autoimmune disease therapeutics market in 2024. The regions covered in the veterinary autoimmune disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the veterinary autoimmune disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary autoimmune disease therapeutics market consists of revenues earned by entities by providing immunosuppressive medications, biologic therapies, supportive therapies and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary autoimmune disease therapeutics market also includes sales of prednisone, mycophenolate mofetil, and methotrexate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Veterinary Autoimmune Disease Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on veterinary autoimmune disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for veterinary autoimmune disease therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The veterinary autoimmune disease therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Corticosteroids; Azathioprine; Cyclosporine; Mycophenolate; Leflunomide; Cyclophosphamide; Levothyroxine; Folic Acid; Hydroxychloroquine; Chloroquine
• 2) By Animal Type: Companion Animals; Livestock Animals; Other Animals
• 3) By Disease: Hypothyroidism; Pemphigus Disease; Canine Lupus; Auto-Immune Hemolytic Anemia; Bullous Pemphigoid; Discoid Lupus Erythematosus (DLE); Immune-Related Arthritis; Other Diseases
• 4) By Distribution Channel: Veterinary Hospitals; Veterinary Clinics
• Subsegments:
• 1) By Corticosteroids: Prednisone; Prednisolone; Dexamethasone; Methylprednisolone; Triamcinolone
• 2) By Azathioprine: Azathioprine Oral Tablets; Azathioprine Injectable Formulation
• 3) By Cyclosporine: Oral Cyclosporine (Atopica); Injectable Cyclosporine
• 4) By Mycophenolate: Mycophenolate Mofetil (Oral Form); Mycophenolate Sodium (Injectable Form)
• 5) By Leflunomide: Leflunomide Tablets (Oral); Leflunomide Injection
• 6) By Cyclophosphamide: Oral Cyclophosphamide; Injectable Cyclophosphamide
• 7) By Levothyroxine: Levothyroxine Sodium Tablets (Oral); Levothyroxine Sodium Injection
• 8) By Folic Acid: Folic Acid Supplements (Oral); Injectable Folic Acid
• 9) By Hydroxychloroquine: Hydroxychloroquine Tablets (Oral); Hydroxychloroquine Injectable Formulation
• 10) By Chloroquine: Chloroquine Tablets (Oral); Chloroquine Injectable Formulation
• Companies Mentioned: Pfizer Inc; Merck & Co Inc; AbbVie Inc.; Sanofi S.A.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Veterinary Autoimmune Disease Therapeutics Market Characteristics

3. Veterinary Autoimmune Disease Therapeutics Market Trends And Strategies

4. Veterinary Autoimmune Disease Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Veterinary Autoimmune Disease Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Veterinary Autoimmune Disease Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Veterinary Autoimmune Disease Therapeutics Market Growth Rate Analysis
• 5.4. Global Veterinary Autoimmune Disease Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Veterinary Autoimmune Disease Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Veterinary Autoimmune Disease Therapeutics Total Addressable Market (TAM)

6. Veterinary Autoimmune Disease Therapeutics Market Segmentation

• 6.1. Global Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Azathioprine
• Cyclosporine
• Mycophenolate
• Leflunomide
• Cyclophosphamide
• Levothyroxine
• Folic Acid
• Hydroxychloroquine
• Chloroquine
• 6.2. Global Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Companion Animals
• Livestock Animals
• Other Animals
• 6.3. Global Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypothyroidism
• Pemphigus Disease
• Canine Lupus
• Auto-Immune Hemolytic Anemia
• Bullous Pemphigoid
• Discoid Lupus Erythematosus (DLE)
• Immune-Related Arthritis
• Other Diseases
• 6.4. Global Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Veterinary Hospitals
• Veterinary Clinics
• 6.5. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Prednisolone
• Dexamethasone
• Methylprednisolone
• Triamcinolone
• 6.6. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Azathioprine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azathioprine Oral Tablets
• Azathioprine Injectable Formulation
• 6.7. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Cyclosporine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Cyclosporine (Atopica)
• Injectable Cyclosporine
• 6.8. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Mycophenolate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mycophenolate Mofetil (Oral Form)
• Mycophenolate Sodium (Injectable Form)
• 6.9. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Leflunomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leflunomide Tablets (Oral)
• Leflunomide Injection
• 6.10. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Cyclophosphamide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Cyclophosphamide
• Injectable Cyclophosphamide
• 6.11. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Levothyroxine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levothyroxine Sodium Tablets (Oral)
• Levothyroxine Sodium Injection
• 6.12. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Folic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Folic Acid Supplements (Oral)
• Injectable Folic Acid
• 6.13. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Hydroxychloroquine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydroxychloroquine Tablets (Oral)
• Hydroxychloroquine Injectable Formulation
• 6.14. Global Veterinary Autoimmune Disease Therapeutics Market, Sub-Segmentation Of Chloroquine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chloroquine Tablets (Oral)
• Chloroquine Injectable Formulation

7. Veterinary Autoimmune Disease Therapeutics Market Regional And Country Analysis

• 7.1. Global Veterinary Autoimmune Disease Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Veterinary Autoimmune Disease Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Veterinary Autoimmune Disease Therapeutics Market

• 8.1. Asia-Pacific Veterinary Autoimmune Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Veterinary Autoimmune Disease Therapeutics Market

• 9.1. China Veterinary Autoimmune Disease Therapeutics Market Overview
• 9.2. China Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Veterinary Autoimmune Disease Therapeutics Market

• 10.1. India Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Veterinary Autoimmune Disease Therapeutics Market

• 11.1. Japan Veterinary Autoimmune Disease Therapeutics Market Overview
• 11.2. Japan Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Veterinary Autoimmune Disease Therapeutics Market

• 12.1. Australia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Veterinary Autoimmune Disease Therapeutics Market

• 13.1. Indonesia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Veterinary Autoimmune Disease Therapeutics Market

• 14.1. South Korea Veterinary Autoimmune Disease Therapeutics Market Overview
• 14.2. South Korea Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Veterinary Autoimmune Disease Therapeutics Market

• 15.1. Western Europe Veterinary Autoimmune Disease Therapeutics Market Overview
• 15.2. Western Europe Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Veterinary Autoimmune Disease Therapeutics Market

• 16.1. UK Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Veterinary Autoimmune Disease Therapeutics Market

• 17.1. Germany Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Veterinary Autoimmune Disease Therapeutics Market

• 18.1. France Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Veterinary Autoimmune Disease Therapeutics Market

• 19.1. Italy Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Veterinary Autoimmune Disease Therapeutics Market

• 20.1. Spain Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Veterinary Autoimmune Disease Therapeutics Market

• 21.1. Eastern Europe Veterinary Autoimmune Disease Therapeutics Market Overview
• 21.2. Eastern Europe Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Veterinary Autoimmune Disease Therapeutics Market

• 22.1. Russia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Veterinary Autoimmune Disease Therapeutics Market

• 23.1. North America Veterinary Autoimmune Disease Therapeutics Market Overview
• 23.2. North America Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Veterinary Autoimmune Disease Therapeutics Market

• 24.1. USA Veterinary Autoimmune Disease Therapeutics Market Overview
• 24.2. USA Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Veterinary Autoimmune Disease Therapeutics Market

• 25.1. Canada Veterinary Autoimmune Disease Therapeutics Market Overview
• 25.2. Canada Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Veterinary Autoimmune Disease Therapeutics Market

• 26.1. South America Veterinary Autoimmune Disease Therapeutics Market Overview
• 26.2. South America Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Veterinary Autoimmune Disease Therapeutics Market

• 27.1. Brazil Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Veterinary Autoimmune Disease Therapeutics Market

• 28.1. Middle East Veterinary Autoimmune Disease Therapeutics Market Overview
• 28.2. Middle East Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Veterinary Autoimmune Disease Therapeutics Market

• 29.1. Africa Veterinary Autoimmune Disease Therapeutics Market Overview
• 29.2. Africa Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Animal Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Veterinary Autoimmune Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Veterinary Autoimmune Disease Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Veterinary Autoimmune Disease Therapeutics Market Competitive Landscape
• 30.2. Veterinary Autoimmune Disease Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Veterinary Autoimmune Disease Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline
• 31.2. Takeda Pharmaceutical Company
• 31.3. Amgen Inc.
• 31.4. Teva Pharmaceuticals Industries Ltd.
• 31.5. Zoetis Inc
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Sumitomo Pharma Co. Ltd.
• 31.8. IDEXX Laboratories Inc.
• 31.9. Cipla Inc.
• 31.10. Mallinckrodt Pharmaceuticals
• 31.11. Virbac S.A
• 31.12. Dechra Pharmaceuticals plc
• 31.13. Neogen Corporation
• 31.14. Vetoquinol S.A.
• 31.15. Norbrook Laboratories Limited

32. Global Veterinary Autoimmune Disease Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Veterinary Autoimmune Disease Therapeutics Market

34. Recent Developments In The Veterinary Autoimmune Disease Therapeutics Market

35. Veterinary Autoimmune Disease Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Veterinary Autoimmune Disease Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Veterinary Autoimmune Disease Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Veterinary Autoimmune Disease Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer